Medexus Pharmaceuticals Inc.
MEDXF
Get informed when a big investor buys or sells
+ FollowMarket Cap$156.72M
Close$
$1.07
69.2% downside
Current Fair Value
69.2% downsideOvervalued by 69.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $156.72 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.07 |
| Beta | 1.68 |
| Outstanding Shares | 31,830,576 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -45.5 |
|---|---|
| PEG | -1655.31 |
| Price to Sales | 1.16 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$25.20 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$26.82 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Medexus Pharmaceuticals Inc.
90 employees
CEO: Kenneth d'Entremont Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. I...